

PATENT COOPERATION TREATY

From the
INTERNATIONAL SEARCHING AUTHORITY

To:

PCT

**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY**

(PCT Rule 43bis.1)

		Date of mailing (day/month/year)
Applicant's or agent's file reference p2003176965		FOR FURTHER ACTION See paragraph 2 below
International application No. PCT/JP2004/008710	International filing date (day/month/year) 21.06.2004	Priority date (day/month/year) 20.06.2003
International Patent Classification (IPC) or both national classification and IPC		
Applicant KOBAYASHI PHARMACEUTICAL CO., LTD.		

1. This opinion contains indications relating to the following items:

- | | | |
|-------------------------------------|--------------|--|
| <input checked="" type="checkbox"/> | Box No. I | Basis of the opinion |
| <input type="checkbox"/> | Box No. II | Priority |
| <input type="checkbox"/> | Box No. III | Non-establishment of opinion with regard to novelty, inventive step and industrial applicability |
| <input type="checkbox"/> | Box No. IV | Lack of unity of invention |
| <input checked="" type="checkbox"/> | Box No. V | Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement |
| <input checked="" type="checkbox"/> | Box No. VI | Certain documents cited |
| <input type="checkbox"/> | Box No. VII | Certain defects in the international application |
| <input type="checkbox"/> | Box No. VIII | Certain observations on the international application |

2. **FURTHER ACTION**

If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further options, see Form PCT/ISA/220.

3. For further details, see notes to Form PCT/ISA/220.

Name and mailing address of the ISA/JP	Authorized officer
Facsimile No.	Telephone No.

WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY

International application No.
PCT/JP2004/008710

Box No. I Basis of this opinion

1. With regard to the language, this opinion has been established on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

This opinion has been established on the basis of a translation from the original language into the following language _____, which is the language of a translation furnished for the purposes of international search (under Rule 12.3 and 23.1(b)).
2. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:
 - a. type of material

a sequence listing
 table(s) related to the sequence listing
 - b. format of material

in written format
 in computer readable form
 - c. time of filing/furnishing

contained in the international application as filed.
 filed together with the international application in computer readable form.
 furnished subsequently to this Authority for the purposes of search.
3. In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
4. Additional comments:

**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY**

International application No.	PCT/JP2004/008710
-------------------------------	-------------------

Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement																									
<p>1. Statement</p> <table> <tr> <td align="center">Novelty (N)</td> <td>Claims</td> <td><u>3, 4</u></td> <td align="center">YES</td> </tr> <tr> <td></td> <td>Claims</td> <td><u>1, 2</u></td> <td align="center">NO</td> </tr> <tr> <td align="center">Inventive step (IS)</td> <td>Claims</td> <td><u>3, 4</u></td> <td align="center">YES</td> </tr> <tr> <td></td> <td>Claims</td> <td><u>1, 2</u></td> <td align="center">NO</td> </tr> <tr> <td align="center">Industrial applicability (IA)</td> <td>Claims</td> <td><u>1-4</u></td> <td align="center">YES</td> </tr> <tr> <td></td> <td>Claims</td> <td></td> <td align="center">NO</td> </tr> </table>		Novelty (N)	Claims	<u>3, 4</u>	YES		Claims	<u>1, 2</u>	NO	Inventive step (IS)	Claims	<u>3, 4</u>	YES		Claims	<u>1, 2</u>	NO	Industrial applicability (IA)	Claims	<u>1-4</u>	YES		Claims		NO
Novelty (N)	Claims	<u>3, 4</u>	YES																						
	Claims	<u>1, 2</u>	NO																						
Inventive step (IS)	Claims	<u>3, 4</u>	YES																						
	Claims	<u>1, 2</u>	NO																						
Industrial applicability (IA)	Claims	<u>1-4</u>	YES																						
	Claims		NO																						
<p>2. Citations and explanations:</p> <p>Document 1: JP 2003-128583 A (Rohto Pharmaceutical Co., Ltd.) 08 May 2003</p> <p>Document 2: JP 2003-113078 A (Lion Corp.) 18 April 2003</p> <p>Document 3: JP 2003-26575 A (Rohto Pharmaceutical Co., Ltd.) 29 January 2003</p> <p>Document 4: JP 2003-107416 A (Lion Corp.) 09 April 2003</p> <p>Document 1 (example 25), document 2 (example 29), document 3 (examples 14, 17) and document 4 (examples 11-14) each describes an ophthalmic composition containing pyridoxine hydrochloride, chondroitin sulfate and cellulosic polymer. Therefore, the inventions of claims 1 and 2 do not appear to possess novelty or involve an inventive step based on documents 1-4 cited in the ISR.</p>																									

**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY**

International application No. PCT/JP2004/008710

Box No. VI	Certain documents cited		
1. Certain published documents (Rule 43bis.1 and 70.10)			
Application No. Patent No.	Publication date (day/month/year)	Filing date (day/month/year)	Priority date (valid claim) (day/month/year)
JP 2003-183157 A	03.07.2003	19.12.2001	
[EX]			
JP 2003-201241 A	18.07.2003	21.10.2002	22.10.2001
[EX]			
Jp 2003-190249 A	08.07.2003	12.21.2001	
[EX]			
2. Non-written disclosures (Rule 43bis.1 and 70.9)			
Kind of non-written disclosure	Date of non-written disclosure (day/month/year)	Date of written disclosure referring to non-written disclosure (day/month/year)	